Piramal Pharma shares fell over 3% in intraday trading on Tuesday, September 15, following the company's announcement of regulatory observations at its UK facility. This marked the fourth consecutive session of losses for the stock, reflecting investor concerns about the regulatory developments. The shares were trading at a 12.4% discount to their 52-week high of ₹231.93, which was achieved during trade on September 8. Despite the recent decline, the stock has risen over 21% since the beginning of the year and has gained more than 1% over the trailing 12 months. According to the latest shareholding data, more than 64.72% of the company's shares were held by the public, while 34.8% was held by promoters.
Piramal Pharma Ltd announced on Monday (September 14) that the US Food and Drug Administration issued a Form-483 containing seven observations following a Good Manufacturing Practices inspection of its Morpeth facility in the UK. According to the latest regulatory disclosure, the inspection was conducted from September 3 to September 11, 2026. The company stated that the observations relate to enhancements in its practices, procedures and documentation. The inspection concluded with the issuance of a Form-483, which documented seven observations related to practices, procedures, and documentation. These observations are primarily related to enhancements needed in the company's existing practices, procedures, and documentation.
As reported by CNBC TV18, Piramal Pharma said it is addressing the observations and preparing a detailed response for submission to the US FDA within the stipulated timeline. The company emphasized its commitment to maintaining the highest standards of compliance and stated it will work closely with the agency to comprehensively address all seven observations. A Form 483 represents a list of observations made during the inspection and is issued by USFDA inspectors after completion, but does not represent a final FDA determination regarding the facility's GMP compliance. The company is actively addressing these points and preparing a comprehensive response to be submitted to the US FDA within the mandated timeline.
According to the company's latest disclosure, after Form 483 is issued, the company is given 15 days to submit its response to the USFDA explaining what steps the company will take to resolve the observations made by the USFDA. This regulatory process allows companies to demonstrate their commitment to addressing identified compliance issues and outlines corrective actions planned for implementation. The company has disclosed that the U.S. Food and Drug Administration (FDA) conducted a routine inspection of its manufacturing facility located in Morpeth, UK, focusing on Good Manufacturing Practices (GMP).
